Targeted News Service

AstraZeneca: ENHERTU Showed Clinically Meaningful And Durable Responses Across Multiple HER2-Expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
March 07, 2023

WILMINGTON, Delaware, March 7 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo's ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.

ENH . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form